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Matrix metalloproteinases (MMPs) are secreted proteinases that have physiologic roles
in degradation and remodeling of extracellular matrix (ECM) in almost all tissues.
However, their excessive production in disease conditions leads to many pathological
features including tissue breakdown, inflammation, cell death, and fibrosis. Duchenne
Muscular dystrophy (DMD) is a devastating genetic muscle disorder caused by partial
or complete loss of cytoskeletal protein dystrophin. Progressive muscle wasting in DMD
is accompanied by myofiber necrosis followed by cycles of regeneration and degeneration
and inflammation that eventually result in replacement of myofiber by connective and
adipose tissues. Emerging evidence suggests that gene expression and the activity
of various MMPs are aberrantly regulated in muscle biopsies from DMD patients and
in skeletal muscle of animal models of DMD. Moreover, a few studies employing
genetic mouse models have revealed that different MMPs play distinct roles in disease
progression in DMD. Modulation of the activity of MMPs improves myofiber regeneration
and enhances the efficacy of transplantation and engraftment of muscle progenitor cells
in dystrophic muscle in mouse models of DMD. Furthermore, recent reports also suggest
that some MMPs especially MMP-9 can serve as a biomarker for diagnosis and prognosis
of DMD. In this article, we provide a succinct overview of the regulation of various MMPs
and their therapeutic importance in DMD.
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INTRODUCTION
Skeletal muscle is composed of predominantly myofibers and
responsible for almost all voluntary movements of the body.
Myofibers are syncytium formed from the fusion of mononu-
cleated myoblasts during embryonic development (Hindi et al.,
2013a). Individual myofibers are surrounded by basement mem-
brane, a thin layer of connective tissue composed of an internal
basal lamina directly linked to sarcolemma and an external fib-
rillar lamina connected to extracellular matrix (ECM) in skeletal
muscle (Sanes, 2003). Basement membrane and ECM are crit-
ical to maintaining structural integrity and normal function
and to providing biochemical support to skeletal muscle (Sanes,
2003; Kjaer, 2004). Genetic studies in animals and humans have
provided evidence that the loss of any of several components
of ECM-basement membrane-sarcolemma-cytoskeleton network
can lead to myopathy (Allamand and Campbell, 2000; Cohn
and Campbell, 2000). Moreover, a number of extracellular or
membrane-associated proteases, which get activated in specific
disease states, can cause myopathy through proteolysis of the
components of this network (Figure 1) (Nagase and Woessner,
1999; Kjaer, 2004; Zhong et al., 2006; Michaluk et al., 2007;
Page-McCaw et al., 2007).
Muscular dystrophy refers to a group of genetic diseases
which cause progressive degeneration of skeletal muscle fibers
leading to severe pain, disability, and eventually death (Emery,
2002). The primary cause for various forms of muscular dystro-
phies is the mutations in individual genes that encode a wide
variety of proteins including extracellular and transmembrane
and membrane-associated proteins, cytoplasmic enzymes, and
nuclear matrix proteins (Campbell, 1995; Blake et al., 2002).
Duchennemuscular dystrophy (DMD) is themost common form
of muscular dystrophy which afflicts 1 out of 3500 male births.
DMD is caused by mutations in the DMD locus (Hoffman et al.,
1987). Dystrophin is a critical component of a large complex
known as dystrophin-associated glycoprotein complex (DGC)
presents on plasmamembrane ofmyofibers (Hoffman et al., 1987;
Blake et al., 2002). Dystrophin stabilizes cells by linking actin
filaments, intermediate filaments, and microtubules to trans-
membrane complexes (Prins et al., 2009). Loss of dystrophin leads
to disruption of DGC complex, membrane instability, increased
susceptibility to mechanical stress, and finally degeneration of
myofibers (Rando, 2001). While skeletal muscle has extraordi-
nary ability to regenerate in response to injury, the regenerative
capacity of myofibers is compromised in DMD potentially due
to exhaustion of satellite cells (muscle stem cells) as a result of
chronic injury (Price et al., 2007).
It is now increasingly evident that the primary deficiency of
dystrophin in skeletal and cardiac muscle results in the activation
of several secondary processes such as calcium influx, infiltra-
tion of muscle tissue by inflammatory immune cells, accretion of
proinflammatory and profibrogenic cytokines, activation of vari-
ous proteolytic enzymes leading to ECM breakdown, and defects
in clearance of damaged organelles through autophagy which all
contribute to muscle wasting and disease progression in DMD
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FIGURE 1 | Schematic representation of DGC and components of ECM
targeted by MMPs in skeletal muscle. Dystrophin stabilizes muscle cells by
linking F-actin, intermediate filaments and microtubules to transmembrane
DGC and ECM. Loss of dystrophin causes sarcolemma instability and
increases susceptibility of sarcolemma to mechanical stress. MMPs are
secreted by several cell types in skeletal muscle and cause proteolysis of
specific substrates. MMP-2 and MMP-9 degrade collagen type IV. MMP-9
also degrades collagen type I, III, and V in interstitial space and cleaves
β-dystroglycan, an important component of DGC. MMP-9 also converts
membrane-bound latent TGF-β into active form by proteolytic cleavage.
Binding of TIMPs inhibits the catalytic activity of MMPs. DGC,
dystrophin-associated glycoprotein complex; ECM, extracellular matrix; MMP,
matrix metalloproteinase; TIMP, tissue inhibitor of MMPs; TGF-β,
transforming growth factor-β.
(Shin et al., 2013). Accumulating evidence further suggests that
DGC has an important signaling role in cardiac and skeletal mus-
cle (Rando, 2001). Loss of dystrophin or other components of
DGC leads to aberrant activation of several intracellular signaling
pathways such as nuclear factor-kappa B (NF-κB), mitogen-
activated protein kinases (MAPK), and phosphatidylinositol 3-
kinase (PI3K)/Akt in skeletal muscle (Kumar and Boriek, 2003;
Kumar et al., 2004; Acharyya et al., 2007; Bhatnagar and Kumar,
2010; Shi et al., 2013). Abnormal myogenic signaling has also
been reported in other forms of muscular dystrophies that result
from loss of nuclear membrane proteins or cytoplasmic enzymes
suggesting that signaling defect is common to all types of mus-
cular dystrophies which can potentially perpetuate dystrophic
phenotype through modulating the activity of nuclear transcrip-
tion factors and gene expression of specific effector proteins
(Bhatnagar and Kumar, 2010).
Several genome-wide studies have suggested that the expres-
sion levels of a number of inflammatory molecules and reg-
ulators of ECM are highly disrupted in muscle biopsies from
DMD patients and in skeletal muscle of animal models of DMD
(Haslett et al., 2002; Porter et al., 2002; Kumar et al., 2010; Shin
et al., 2013). Matrix metalloproteinases (MMPs) are one such
class of molecules whose expression and activation is disrupted
and appear to play a prominent role in disease progression in
DMD (Table 1). In this article, we discuss the role of MMPs in
pathogenesis of muscular dystrophy with emphasis on DMD.
MATRIX METALLOPROTEINASES (MMPs)
MMPs are zinc-containing, calcium-dependent proteases that
have an important role in ECM remodeling, inflammation,
fibrosis, and activation of various latent cytokines, cell adhe-
sion molecules, and growth factors in both physiological and
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Table 1 | Role of different MMPs in muscular dystrophy studied by pharmacological or genetic approaches.
Targeted MMP(s) Approach to inhibit activity Role in muscular dystrophy References
Pan-MMPs Pharmacological Cause myofiber injury
Mediate inflammation
Reduce levels of β-dystroglycan
Inhibit myofiber regeneration
Reduce levels of nNOS
Increase fibrosis
Reduce muscle force production
Activate MAPK and AP-1
Reduces life-span of dystrophic mice
Girgenrath et al., 2009; Kumar et al., 2010;
Percival et al., 2012; Pereira et al., 2012, 2014
MMP-2 Genetic Improves vascularization
Improves myofiber regeneration
Promotes fiber growth
Increases levels of VEGF-A
Miyazaki et al., 2011
MMP-9 Genetic Causes myofiber injury
Increase inflammation
Reduces levels of β-dystroglycan and nNOS
Increases fibrosis
Reduces satellite cell number
Reduces myofiber regeneration
Reduces engraftment of progenitor cells
Increases levels of active TGF-β
Activates NF-κB and AP-1
Activates MAPK and Akt kinase
Inhibits notch signaling
Inhibits canonical Wnt signaling
Causes cardiomyopathy
Reduces skeletal and cardiac muscle function
Li et al., 2009b; Dahiya et al., 2011a,b; Hindi
et al., 2013b
MMP-10 Genetic Improves myofiber regeneration
Inhibits dystrophic phenotypes
Bobadilla et al., 2014
pathological conditions (Vu and Werb, 2000; Page-McCaw et al.,
2007). Based on their substrate specificity, MMPs are classified in
four groups: the collagenases (MMP-1, -8, and -13), the gelati-
nases (MMP-2 and -9), the stromelysins (MMP-3, -10, and -11)
and a heterogeneous group which contain matrilysin (MMP-7),
metallo-elastase (MMP-12), enamelysin (MMP-20), endometase
(MMP-26), and epilysin (MMP-28). MMPs are generally syn-
thesized as secreted or transmembrane proenzymes which are
processed to an active enzyme by the removal of an amino-
terminal propeptide (Chakraborti et al., 2003). Once activated,
MMPs are subject to inhibition by the tissue inhibitors of metallo-
proteinases (TIMPs) that bind to MMPs non-covalently (Vu and
Werb, 2000; Page-McCaw et al., 2007).While the catalytic domain
of MMPs is structurally similar, there are several differences in
substrate specificity, cellular localization, membrane binding and
regulation, making these a family of proteolytic enzymes having
distinct functions (Nagase and Woessner, 1999; Vu and Werb,
2000; Page-McCaw et al., 2007).
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are the two
major MMPs which degrade type IV collagen, an integral part
of basement membrane (Turpeenniemi-Hujanen et al., 1985; Vu
and Werb, 2000; Page-McCaw et al., 2007). MMP-9 is expressed
during early embryonic development but is largely dormant in
normal adult tissues. Gene expression and activation of MMP-
9 are rapidly increased upon tissue injury suggesting its role in
repair process, release of growth factors, and modulation of ECM
for cell migration (Ram et al., 2006). By contrast, persistent pres-
ence of MMP-9 contributes to inflammation and tissue destruc-
tion in many disease states including chronic wounds (Ladwig
et al., 2002; Rayment et al., 2008), heart failure (Chu et al., 2011),
rheumatic arthritis (Munoz-Valle et al., 2003), fibrotic lung dis-
ease (Fukuda et al., 1998), dilated cardiomyopathy (Ducharme
et al., 2000), multiple sclerosis (Fernandes et al., 2009), asthma
(Corry et al., 2004), and cancer (Turpeenniemi-Hujanen et al.,
1985; Chandler et al., 1997; Martin et al., 2008; Xu et al., 2010).
MMP-2 which is constitutively expressed by many cell types
including skeletal muscle has little regulation at the transcrip-
tional level and most of the regulation takes place at the post-
transcriptional level (Kherif et al., 1999; Nagase and Woessner,
1999; Chakraborti et al., 2003; Das et al., 2003). However, tran-
scription of MMP-9 can be highly induced by numerous agents
including cytokines, growth factors, cell–cell interaction, and cell-
ECM adhesion molecules (Chakraborti et al., 2003). MMP-9
activity is regulated at various levels: gene transcription, synthesis,
secretion, activation, inhibition, and glycosylation (Chakraborti
et al., 2003). MMP-9 gene expression is under the control of a
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2.2 kb upstream regulatory sequence containing binding sites for
multiple transcription factors such as activator protein 1 (AP-1),
NF-κB, specificity protein 1 (SP-1) which are conserved in differ-
ent mammalian species (Gum et al., 1996; Nair and Boyd, 2005;
Ram et al., 2006). Indeed, inflammatory cytokines TNF-α and
TWEAK increase the gene expression of MMP-9 in skeletal mus-
cle through activation of NF-κB and AP-1 transcription factors
(Srivastava et al., 2007; Li et al., 2009a; Tajrishi et al., 2014).
Collagens are some of the most important proteolytic tar-
gets of MMPs in various tissues including skeletal muscle.
Intramuscular connective tissue in skeletal muscle constitutes
multiple collagen types (Kjaer, 2004). Whereas type IV collagen
dominates the basement membrane adjacent to the sarcolemma,
the fibrillar collagens type I and III (and to some extent type
V) dominate the epi-, peri-, and endomysium in skeletal mus-
cle (Koskinen et al., 2000; Ahtikoski et al., 2003). Even though
collagen IV is the major substrate, MMP-9 can also degrade (but
to a much lower extent) collagen I, III, and V present in skele-
tal muscle ECM (Vu and Werb, 2000; Mott and Werb, 2004).
Furthermore, many other proteins such as laminin, fibronectin,
entactin, elastin, and gelatin present in skeletal muscle ECM are
other potential proteolytic targets for MMP-9 (Lewis et al., 2001;
Chakraborti et al., 2003; Das et al., 2003). A few recent stud-
ies have demonstrated that MMP-9 cleaves β-dystroglycan, an
important component of DGC in skeletal muscle (Zhong et al.,
2006; Michaluk et al., 2007). In addition, it has been found that
MMP-9 proteolytically converts latent membrane-bound trans-
forming growth factor (TGF)-β into active protein which might
be one of the mechanisms by which MMP-9 promotes fibro-
sis in diseased muscle (Figure 1) (Yu and Stamenkovic, 2000;
Page-McCaw et al., 2007).
DEREGULATION OF MMPS IN MUSCULAR DYSTROPHY
There are several reports suggesting that gene expression and
activation of various MMPs are deregulated in DMD patients.
The first evidence about elevated activity of MMPs came from
the studies by Sohar et al demonstrating that the serum levels
of MMP-7 along with lysosomal cysteine proteinases (cathepsin
H and L) are increased in DMD patients (Sohar et al., 1988).
Since chronic degradation of ECM generally leads to fibrosis, von
Moers et al studied expression of fibrolytic MMP-1 and MMP-2
and their physiological inhibitors TIMP-1 and TIMP-2 in muscle
biopsies from DMD patients (von Moers et al., 2005). A sig-
nificant increase in gene expression and activity of MMP-2 was
evident in DMD muscle compared with controls. Furthermore,
gene expression of TIMP-1 and TIMP-2 was increased in DMD
muscle indicating deregulation of MMP activation (von Moers
et al., 2005). Zanotti et al employed a cell culture model to
investigate whether the expression of the components of ECM
is altered in DMD muscle cells (Zanotti et al., 2007). This study
showed that mRNA levels of several ECM molecules such as
TGF-β1, myostatin, collagen I and VI, MMP-2, TIMP-1, and
TIMP-2 were significantly higher whereas no significant differ-
ences were noticeable in mRNA levels of MMP-9 and TIMP-3 in
DMD myotubes compared to normal myotubes (Zanotti et al.,
2007). Interestingly, a progressive increase in levels of MMP-9
has recently been reported in serum of DMD patients (Nadarajah
et al., 2011). Together, these findings suggest that while levels of
MMP-9 along with other MMPs are increased, myofibers may not
be the cellular source of MMP-9 in DMD patients (Zanotti et al.,
2007; Nadarajah et al., 2011). Indeed, increased gene expression
of various ECM components and MMPs has also been reported
in cultured myofibroblasts from patients with DMD compared
with healthy controls (Zanotti et al., 2010) further supporting the
premise that multiple cell types may contribute to the increased
levels of various MMPs in DMD patients.
Higher levels of MMPs have also been observed in animal
models of muscular dystrophy. Fukushima et al studied MMPs
and TIMPs in a canine X-linked muscular dystrophy in Japan
(CXMDJ) model of DMD (Fukushima et al., 2007). They found
that the expression levels and activation of MMP-2 and MMP-
9 and their regulatory molecules such as MT1-MMP, TIMP-1,
TIMP-2, and RECK (Reversion-inducing-cysteine-rich protein
with kazal motifs) are significantly increased in dystrophic mus-
cle of CXMDJ dogs compared to normal controls. MMP-2 and
MMP-9 were predominantly localized in areas filled with degen-
erating and regeneratingmyofibers with cellular infiltrates further
implying that inflammatory cells and fibroblasts are important
sources of these gelatinases in dystrophic muscle (Fukushima
et al., 2007).
Kherif et al provided initial evidence that gelatinolytic activ-
ity of MMP-2 and MMP-9 are increased in skeletal muscle of
mdx (a mouse model of DMD) mice (Kherif et al., 1999). Since
the activation of MMP-2 and MMP-9 is also increased in skeletal
muscle after cardiotoxin-mediated injury, the authors suggested
that theseMMPsmay have a role inmyofiber regeneration (Kherif
et al., 1999). However, it is notable that in normal skeletal muscle,
the activities ofMMP-2 andMMP-9 are increased only transiently
after injury and return back to basal levels as the initial phases of
regeneration subside. By contrast, MMP-2 and MMP-9 are con-
stitutively expressed in dystrophic muscle of mdx mice which
can lead to other changes in skeletal muscle microenvironment
such as excessive remodeling of ECM and basement membrane
leading to fibrosis. Roma et al. measured the levels of MMP-
9, myosin heavy chain, utrophin, and β-dystroglycan protein in
relation to the intensity of necrosis-regeneration at different age
points in mdx mice (Roma et al., 2004). Protein levels of MMP-
9 starts increasing at around 10 days which peaked between 25
and 60 days. During this period, the protein levels of utrophin
and β-dystroglycan were significantly reduced in mdx mice indi-
cating post-translational modification of structural protein in
the myofibers of mdx mice (Roma et al., 2004). Interestingly, β-
dystroglycan has now been found as an important target ofMMP-
9 leading to a characteristic 30 kDa fragment (Zhong et al., 2006;
Michaluk et al., 2007). The 30 kDa fragment of β-dystroglycan
has also been found to be increased in sarcoglycanopathy and
DMD further suggesting that proteolysis of β-dystroglycan may
contribute to skeletal muscle degeneration by disrupting the link
between the ECM and sarcolemma (Matsumura et al., 2005).
Increased production of MMP-9 with concomitant increase in
the 30 kDa fragment of β-dystroglycan is also noticeable in
diaphragm of mdx mice (Hnia et al., 2007). Moreover, immuno-
histochemical studies have suggested that similar to the CXMDJ
model, MMP-9 is produced predominantly by macrophages and
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potentially other infiltrating cells in dystrophic muscle of mdx
mice (Li et al., 2009b).
Recent studies have suggested that there is a cooperative inter-
action between various MMPs to induce tissue degeneration in
multiple disease condition (Chakraborti et al., 2003). By per-
forming real-time PCR array, we have reported that in addition
to MMP-2 and MMP-9, the gene expression of several other
MMPs such as MMP-3, -8, -10, -12, -13, -14, and -15 and
TIMP-1 and -3 is increased in gastrocnemius muscle of mdx
mice (Kumar et al., 2010). Our study also showed that pan-
MMP activity was significantly elevated in dystrophic muscle of
mdx compared with their normal counterparts (Kumar et al.,
2010). Furthermore, protein levels and gelatinolytic activity of
MMP-2 and MMP-9 are increased in cardiac muscle of mdx and
mdx/utrophin double knockout mice (Dahiya et al., 2011a; Delfin
et al., 2012).
TARGETING MMPs USING PHARMACOLOGICAL
COMPOUNDS
Since MMPs are also highly deregulated in cancer patients where
they are linked to metastasis, several compounds have been devel-
oped to inhibit the activation of MMPs. Batimastat, a collagen
peptide based hydroxamic acid, is among the first synthetic MMP
inhibitors (MMPIs) developed to treat cancer (Fingleton, 2007,
2008). It mimics the site in the collagen substrate which is cleaved
by MMPs. Batimastat functions by a competitive, reversible inhi-
bition and effectively blocks the activities of MMP-1, MMP-2,
MMP-3, MMP-7, MMP-8, MMP-9, and MMP-14 (Brown, 1995;
Grams et al., 1995; Rasmussen and McCann, 1997). We stud-
ied the effects of batimastat in muscle pathology in mdx mice.
Interestingly, chronic administration of batimastat in young mdx
mice (starting at the age of 2-week) for a total of 5 weeks signifi-
cantly reduced many pathological features in skeletal muscle such
as infiltration of muscle tissue by inflammatory macrophages,
gene expression of TNFα and cell adhesion molecules, myofiber
necrosis, and fibrosis. The improvement in muscle pathology
was also evident by the findings that diaphragm muscle force
production in isometric contractions was significantly increased
in batimastat-treated mdx mice compared to those treated with
vehicle alone (Kumar et al., 2010). Consistent with proteolytic
functions of MMPs, the levels of β-dystroglycan and neuronal
nitric oxide synthase (nNOS) were improved in skeletal muscle
of mdx mice on treatment with batimastat (Kumar et al., 2010).
Furthermore, our study revealed that batimastat diminished the
activation of MAPKs and transcription factor AP-1 in skeletal
muscle of mdxmice. Although a short-term study, it provided the
first evidence that pan-MMP inhibition is effective in reducing
the severity of disease in a mouse model of DMD.
Tetracycline derivatives such as doxycycline and minocy-
cline have been shown to non-specifically inhibit the activ-
ity of various proteases especially MMPs. Pereira et al. treated
both young and aged mdx mice with doxycycline in drink-
ing water for 1 month. This treatment significantly reduced
myofiber necrosis, inflammation and fibrosis and improved mus-
cle strength (Pereira et al., 2012). A more recent report from
the same group documented that doxycycline reduces the lev-
els of MMP-9 and TNF-α in dystrophic muscle of mdx mice
(Pereira et al., 2014). Suramin, which inhibits binding of trans-
forming growth factor-beta 1 (TGF-β1) to its receptor, has been
also found to reduce myofiber necrosis and fibrosis and improve
levels of β-dystroglycan potentially through reducing the levels
of MMP-9 in dystrophic muscle of mdx mice (Taniguti et al.,
2012).
Although activity of MMPs was not studied, tetracycline
derivatives have also been shown to ameliorate myopathy in other
models of muscular dystrophy. Girgenrath et al. have demon-
strated that treatment with doxycycline or minocycline improves
post-natal growth, delays the onset of hind-limb paralysis, and
increases lifespan of the laminin-α2-null mice (a model of con-
genital muscular dystrophy) from ∼32 to 70 days (Girgenrath
et al., 2009). On similar lines, doxycycline improved skeletal mus-
cle pathology in a mouse model of oculopharyngeal muscular
dystrophy (Davies et al., 2005). Moreover, it has been recently
reported that treatment of mdx mice with the phosphodiesterase
5 inhibitor sildenafil (Viagra®, Revatio®) reduces fibrosis and
improves respiratory muscle contractility. Importantly, the lev-
els of MMP-13 were significantly diminished in myofibers of
mdx mice on treatment with sildenafil (Percival et al., 2012).
Collectively, these studies suggest that pharmacological com-
pounds which inhibit the activity ofMMPs have therapeutic value
in muscular dystrophy.
Even though broad spectrum MMP inhibitory compounds
appear to improve myopathy in animal models of muscular dys-
trophy, it is noteworthy that so far no clinical trial using MMPIs
has been considered as truly successful in cancer or other dis-
ease states because of deleterious side effects (Parsons et al., 1997;
Nemunaitis et al., 1998; Macaulay et al., 1999; Bramhall et al.,
2001, 2002a,b; Fingleton, 2007). However, it is also notable that
the first generation MMPIs including batimastat and its deriva-
tives were small peptide mimics that chelate the zinc ion and
block the function of the enzymes. Treatment with these MMPIs
led to the development of a musculoskeletal syndrome (MSS)
that reduced the overall quality of life and withdrawal of patients
from clinical trials (Brown, 1999; Dove, 2002; Fingleton, 2007,
2008). While it is unambiguous that MMPs represent one of the
most important therapeutic targets for various tissue degenera-
tive disorders (Brown, 1999; Dove, 2002; Fingleton, 2007, 2008),
multiple reasons have been cited for the failure of the first gener-
ation broad spectrum MMPIs in clinical trials. A current theory
is that the majority of the side effects associated with MMPIs in
clinical trials are predominantly related to off-target metal (Zn
and Fe) chelation by the first generation MMPIs (Renkiewicz
et al., 2003). Strong evidence that MSS side effects are not related
to MMP inhibition per se comes from the use of other drugs
which do not cause metal chelation. A number of compounds
have been reported to have the ability to block the activity or
expression of MMPs including bisphosphonates (Giraudo et al.,
2004; Ferretti et al., 2005), statins (Wilson et al., 2005; Yasuda
et al., 2007), and antibiotics (Acharya et al., 2004). So far there
is no evidence that treatment with any of these drugs is associ-
ated with MSS suggesting that better designed MMPIs would be
more effective in clinical trials (Acharya et al., 2004). Because of
the high levels of similarity in the catalytic domain of MMPs, it
has been a great challenge to develop drugs which can inhibit the
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activity of a specific MMP. However, there can be other poten-
tial approaches to inhibit MMPs once their specific activators
and regulators are identified. For example, it has been recently
shown that osteopontin up-regulates the expression of MMP-9
in skeletal muscle of mice. Treatment with osteopontin neutraliz-
ing antibody reduced the levels of MMP-9 in dystrophic muscle of
mdxmice (Dahiya et al., 2011a). Small molecules such as microR-
NAs represent another class of molecules which can modulate the
levels of specific MMPs in disease conditions (Xu et al., 2012;
Asuthkar et al., 2013; Wu et al., 2013).
TARGETING MMPs USING GENETIC APPROACHES
MMP-9 is highly overexpressed in dystrophic muscle of mdx
mice. By crossing with Mmp9-knockout mice, we investigated
the role of MMP-9 in skeletal and cardiac muscle pathology in
mdx mice. Our analysis showed that heterozygous or homozy-
gous deletion of Mmp9 gene dramatically reduced serum levels
of creatine kinase (a marker of muscle injury), inflammation,
fibrosis and improved skeletal muscle structure and function
and myofiber regeneration in 8-week old mdx mice (Li et al.,
2009b). Furthermore, genetic ablation of MMP-9 also diminished
serum levels of creatine kinase and improved muscle structure
in 1-year old mdx mice indicating that the continued inhibition
of MMP-9 is effective in reducing muscle injury in mdx mice
(Dahiya et al., 2011b). Although the exact mechanisms by which
excessive production of MMP-9 causes myopathy in mdx mice
remain unclear, our analysis showed that the inhibition of MMP-
9 increased the protein levels of β-dystroglycan and nNOS and
reduced the amounts of active form of TGF-β in myofibers of
mdx mice. Therefore, it is reasonable to speculate that the inhibi-
tion of MMP-9 improves the integrity of DGC on sarcolemma by
preventing excessive degradation of its components. Since TGF-
β increases fibrosis in skeletal muscle, diminished levels of active
TGF-β1 upon inhibition of MMP-9 may be a potential mecha-
nism for amelioration of fibrosis in dystrophic muscle of mdx
mice (Li et al., 2009b).
Intriguingly, deletion of a single allele of Mmp9 gene was suf-
ficient to drastically reduce the frequency of macrophages (also a
major source of MMP-9) and protein levels of MMP-9 by ∼80%
in dystrophic muscle of mdx mice. These findings suggest that
MMP-9 induces its own expression through a positive feed-back
mechanism (Figure 2). Indeed, we have reported that the inhibi-
tion of MMP-9 diminishes the activation of NF-κB and AP-1 in
dystrophicmuscle of mdxmice (Li et al., 2009b) which is in agree-
ment with published reports that the gene expression ofMMP-9 is
regulated by NF-κB and AP-1 (Chakraborti et al., 2003; Srivastava
et al., 2007; Li et al., 2009a). A number of studies have now shown
that the activity of NF-κB is increased in muscle biopsies and
in skeletal muscle of animal models of DMD (Acharyya et al.,
2007; Bhatnagar and Kumar, 2010). Furthermore, inhibition of
NF-κB using either genetic or pharmacological approaches ame-
liorates skeletal muscle pathology in models of DMD (Acharyya
et al., 2007; Li et al., 2008; Bhatnagar and Kumar, 2010). MMP-9
appears to be one of the downstream effector molecules of NF-
κB evident by the findings that treatment with peptide inhibitor
of NF-κB drastically reduced the levels of MMP-9 in diaphragm
of mdx mice (Li et al., 2009b). A cooperative interaction between
FIGURE 2 | Proposed mechanisms of action of MMP-9 in DMD. Lack
of dystrophin leads to destabilization of DGC, increased susceptibility to
contraction-induced injury, and finally degeneration/regeneration of
myofibers. Cycles of fiber degeneration and regeneration augment
inflammatory response with concomitant activation of proinflammatory
transcription factors NF-κB and AP-1. NF-κB, and AP-1 augments the gene
expression of MMP-9. Increased production of MMP-9 also induces
NF-κB and AP-1 activity potentially through proteolytic activation of
various latent cytokines. Persistent presence of high levels of MMP-9
causes fiber necrosis, inflammation, and fibrosis and interferes with
regeneration of damaged myofibers leading to myopathy. AP-1, activator
protein 1; DGC, dystrophin-associated glycoprotein complex; DMD,
Duchenne muscular dystrophy; MMP-9, matrix metalloproteinase-9;
NF-κB, nuclear factor-kappa B.
NF-κB andMMP-9 in pathogenesis of mdxmice is also supported
by the findings that activation of NF-κB and increases in the gene
expression of MMP-9 follow a similar pattern in skeletal muscle
of mdx mice (Kumar and Boriek, 2003; Acharyya et al., 2007; Li
et al., 2009b). This notion is further supported by the findings that
L-arginine, which improves myopathy in mdx mice, diminishes
the expression of inflammatory cytokines and levels of NF-κB and
MMP-9 in dystrophic muscle (Hnia et al., 2008).
There is a plethora of literature demonstrating that the abun-
dance of many MMPs including MMP-9 is increased in response
to a variety of cardiac insults resulting in cardiomyopathy (Tyagi
et al., 1996; Halade et al., 2013). Targeted deletion of MMP-9
in mice has been found to attenuate coronary artery ligation-
induced left ventricle enlargement and accumulation of collagens,
suggesting a role for MMP-9 in cardiac remodeling after ischemic
injury (Ducharme et al., 2000). Studies from our group and oth-
ers have shown that the levels of MMP-9 are also increased in
cardiac muscle of mdx and mdx/utrophin double knockout mice
(Dahiya et al., 2011a; Delfin et al., 2012). We examined the role
of MMP-9 in the development of cardiomyopathy in mdx mice.
Ablation of MMP-9 attenuated injury, inflammation, left ventri-
cle dilation, and fibrosis leading to improvement in heart function
in 1-year old mdx mice. Ablation of MMP-9 also diminished the
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activation of extracellular-regulated kinase 1/2 and Akt/protein
kinase B (PKB) in the cardiac muscle of mdx mice. Furthermore,
inhibition of MMP-9 suppressed the gene expression of MMP-3
andMMP-12 in the heart of mdx mice which is further suggestive
of a cooperative interaction between variousMMPs in the settings
of muscular dystrophy.
Although the mechanisms leading to the increased levels of
MMP-9 remain unknown, proinflammatory cytokines whose
abundance is increased in mdx mice, appear to be some of the
potential stimuli for up-regulation in MMP-9 levels in skele-
tal and cardiac muscle in muscular dystrophy (Acharyya et al.,
2007; Li et al., 2009a; Shin et al., 2013). As mentioned above, a
recent study has demonstrated that protein levels of osteopon-
tin (an important regulator of immune response) are significantly
increased in circulation and dystrophic muscle of mdx mice and
genetic ablation of osteopontin attenuates fibrosis in mdx mice
(Vetrone et al., 2009). Neutralizing antibody against osteopon-
tin reduced the amounts of MMP-9 in dystrophic muscle of mdx
mice suggesting that osteopontin contributes, at least partly, to
the increased amounts of MMP-9 in cardiac and skeletal muscle
of mdx mice (Dahiya et al., 2011a).
In contrast to the role of MMP-9 in mdx mice, it has been
reported that the forced expression of MMP-9 increases vascu-
larization and reduces collagen deposition in skeletal muscle of
12-month old α-sarcoglycan-deficient mice, a mouse model of
limb griddle muscular dystrophy (Gargioli et al., 2008). However,
in this study, placenta growth factor was also used in addition
to MMP-9 (Gargioli et al., 2008). Moreover, it is likely that a
specific MMP may have different roles in various types of mus-
cular dystrophy and it is the muscle microenvironment which
dictates whether the inhibition of a MMP will provide beneficial
or deleterious effects.
Levels of MMP-2 are also increased in dystrophic muscle
of mdx mice (Kherif et al., 1999; Li et al., 2009b). Miyazaki
et al have reported that genetic ablation of MMP-2 in mdx
mice inhibits fiber growth and angiogenesis in skeletal muscle
potentially through diminishing the levels of vascular endothe-
lial growth factor-A, an important angiogenesis-related factor.
Since the levels of β-dystroglycan remained unaffected, it is likely
that only MMP-9 but not MMP-2 is involved in proteolysis
of β-dystroglycan in dystrophic muscle (Miyazaki et al., 2011).
The role of MMP-10 in pathogenesis of mdx mice has also
now been investigated using genetic approaches (Bobadilla et al.,
2014). Similar to MMP-2, MMP-10 also has a positive impact
on skeletal muscle regeneration in mdx mice. The dystrophic
phenotypes are exaggerated by the deletion of Mmp10 gene in
mdx mice. Moreover, knockdown of MMP-10 reduced myofiber
regeneration whereas treatment with recombinant MMP-10 pro-
tein augmented myofiber repair in mdx mice (Bobadilla et al.,
2014). Altogether, these studies using knockout mouse models
have highlighted that not all MMPs are involved in pathogene-
sis of muscular dystrophy and some of them may be activated as
a part of compensatory mechanism to counter muscle damage.
These findings further emphasize the importance of understand-
ing the specific roles of various MMPs and necessity to develop
specific inhibitors for different MMPs before considering them as
therapeutic targets for muscular dystrophy.
MMPs AND STEM-CELL BASED THERAPIES FOR DMD
Recent advancements in stem cell-based therapies have suggested
that the transplantation of stem cells including satellite cells can
be an important approach for the introduction of functional dys-
trophin protein in DMDpatients (Dezawa et al., 2005; Sampaolesi
et al., 2006; Cerletti et al., 2008; Darabi et al., 2008). However,
one of the drawbacks of this approach is that the transplanta-
tion of satellite cells into muscle tissue typically results in poor
engraftment and death of significant amounts of cells, resulting
in little repair of the diseased muscle (Darabi et al., 2008). The
limitation in migration of transplanted cells in skeletal muscle is
also another issue which could be attributed to the presence of
excessive fibrosis and ECM abnormalities (Darabi et al., 2008).
Approaches which reduce secondary changes such as inflamma-
tory response and fibrosis prior to transplantation can potentially
improve the functional engraftment of transplanted cells in dys-
trophic muscles (Qu et al., 1998). In fact, a few studies have
shown that the attenuation of inflammation in dystrophic muscle
improves the effectiveness of cellular therapy in models of DMD
(Qu et al., 1998; Darabi et al., 2008).
Since MMPs play a prominent role in cell migration and
invasion, Pichavant et al investigated the effects of overexpres-
sion of MMP-9 in muscle precursor cells (MPCs) and their
transplantation in skeletal muscle of mice (Pichavant et al.,
2011). They found that overexpression of MMP-9 did not
affect the proliferation, migration, or differentiation; however, it
enhanced the invasion capacity of MPCs in vitro. When MMP-
9 overexpressing MPCs were transplanted in Reg1-null mice, an
improvement in MPC transplantation and migration was notice-
able suggesting that MMP-9 causes ECM remodeling leading
to enhanced transplantation in healthy muscle. We have also
reported that skeletal muscle-specific transgenic overexpression
of a constitutively active mutant of MMP-9 causes hypertrophy
and improves myofiber regeneration upon cardiotoxin-mediated
injury (Dahiya et al., 2011b). However, it is notable that in these
studies, disease-free mice were used and MMP-9 was overex-
pressed by either transplanted MPCs or myofibers which may not
be sufficient to cause the same extent of ECM degradation and
fibrosis that are observed in dystrophic muscle from mdx mice
(Pichavant et al., 2011).
We investigated the role of MMP-9 in engraftment of MPCs
in dystrophic muscle of mdx mice (Hindi et al., 2013b). Our
study showed that the suppression of MMP-9 levels in dystrophic
muscle of recipient mdx mice using genetic approach dramati-
cally improves the engraftment of transplanted wild-type MPCs
resulting in the expression of dystrophin protein in myofibers
of mdx mice (Hindi et al., 2013b). Consistent with myofiber
regeneration (Li et al., 2009b), the engraftment of transplanted
MPCs was better in heterozygous (mdx;Mmp9+/−) mice com-
pared to homozygous (mdx;Mmp9−/−)mice although both these
genotypes showed better efficacy compared to mdx/Mmp9+/+
mice (Hindi et al., 2013b). These results suggest that increased
activity of MMP-9 makes the dystrophic muscle microenvi-
ronment less permissive for the proliferation, differentiation,
and fusion of MPCs. It is notable that deletion of a single
allele of Mmp9 gene reduces the protein levels of MMP-9 up
to ∼80% in dystrophic muscle of mdx mice (Li et al., 2009b).
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Higher MPC engraftment in mdx/Mmp9+/− mice compared
with mdx;Mmp9−/− mice also suggests that a small amount
of MMP-9 may be beneficial for the migration of transplanted
MPCs in dystrophic muscle whereas excessive levels of MMP-
9 causes pathological remodeling leading to poor engraftment
(Hindi et al., 2013b). Mechanistically, it has been found that
the inhibition of MMP-9 reduces the transcript levels of vari-
ous proinflammatory cytokines and increases the proportion of
M2 macrophages (Hindi et al., 2013b). Notch signaling, which
promotes the proliferation of satellite cells (Brack et al., 2008),
was increased in dystrophic muscle of mdx mice upon inhibi-
tion of MMP-9. Furthermore, MMP-9 inhibition augments the
expression of the components of canonical Wnt signaling which
promote myoblast fusion (Brack et al., 2008; Hindi et al., 2013b).
Collectively, these studies in mdx mice have provided initial evi-
dence that the inhibition of MMP-9 in dystrophic muscle can be
a potential approach to improve myofiber regeneration and the
transplantation and engraftment of MPCs.
MMPs AS BIOMARKERS IN DMD
Based on the findings that the activation of various MMPs is
deregulated in muscular dystrophy, it is conceivable that some
of these MMPs can serve as biomarkers for diagnosis and prog-
nosis of muscular dystrophy. Recently, Nadarajah et al measured
the levels of MMP-9, TIMP-1, and osteopontin in a small cohort
of DMD patients subjected to corticosteroid therapy (Nadarajah
et al., 2011). They reported that serum levels of MMP-9 and
TIMP1 (but not osteopontin) were significantly higher in DMD
patients compared to healthy individuals. Levels of MMP-9
(but not TIMP-1) were higher in older, non-ambulant patients,
compared with ambulant patients. Moreover, a progressive age-
dependent increase in the serum levels of MMP-9 was noticeable
suggesting that MMP-9 is linked to the disease progression in
DMD. While the study employed only 63 patients, these findings
suggest that MMP-9 can be used as a potential biomarker for dis-
ease progression and monitoring therapeutic response in DMD
(Nadarajah et al., 2011). Serum levels of a few MMPs (e.g., MT1-
MMP,MMP-2, andMMP-9) have also been found to be increased
in patients with Emery-Dreifuss muscular dystrophy and their
increased levels correlate with dilated cardiomyopathy in these
patients further signifies that MMPs can serve as biomarkers for
diagnosis and prognosis in different types of muscular dystrophy
(Niebroj-Dobosz et al., 2009).
CONCLUDING REMARKS
Studies summarized above suggest that the expression and activ-
ity of multiple MMPs are deregulated and that MMPs can be
important biomarkers and therapeutic targets in muscular dys-
trophy. While MMPIs have been found to mitigate disease pro-
gression in mouse models, genetic studies have provided evidence
that some MMPs (e.g., MMP-2 and MMP-10) may have benefi-
cial roles in muscular dystrophy. Indeed, it is now evident that
different MMPs play distinct roles in various physiological pro-
cesses such as development, cell migration, and host protective
mechanisms. Therefore, before considering the use of MMPIs in
muscular dystrophy patients, it is critical to identify the precise
role of aberrantly regulated MMPs in pathogenesis of muscular
dystrophy. Intense efforts are on in different laboratories and
pharmaceutical companies to develop drugs which can target a
specific MMP in vivo.
There are also outstanding questions regarding the role of
MMPs in muscular dystrophy. For example, the mechanisms of
action of various MMPs in muscular dystrophy remain poorly
understood. It remain unknown how the increased levels of
specific MMPs cause myopathy or improve myofiber regenera-
tion and whether they have similar roles in all types of mus-
cular dystrophy. Understanding these mechanisms will provide
additional drug targets for treatment of muscular dystrophy
patients. Furthermore, the extracellular stimuli which increase
the expression of specific MMPs in dystrophic muscle remain
poorly defined. It is also noteworthy that most of the studies
performed in animal models are short-term. It is yet to be inves-
tigated whether continued inhibition or activation of MMPs for
longer duration will remain beneficial in rodent models and in
higher organisms such as the golden retriever muscular dystro-
phy model. Nevertheless, available literature suggests that MMPs
play an important role in muscular dystrophy.
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